Background/Aims: Peritonitis is a major complication that arises out of peritoneal dialysis (PD), leading to death and loss of mesothelium and peritoneal injury, which may impede PD. We studied the combined impact of inflammatory mediators and PD fluids on mesothelial cell death. Methods: Cultured human mesothelial cells. Results: Inflammatory cytokines (TNF-α and interferon-γ) cooperate with bioincompatible PD fluids containing high glucose degradation product (GDP) concentrations to promote mesothelial cell death. Thus, the inflammatory cytokine cocktail induced a higher rate of death in cells cultured in high GDP PD fluid than in low GDP PD fluid or cell culture medium (cell death expressed as % hypodiploid cells: TNF-α and interferon-γ in RPMI: 14.15 ± 1.68, TNF-α and interferon-γ in 4.25% low GDP PD fluid 13.16 ± 3.29, TNF-α and interferon-γ in 4.25% high GDP PD fluid 25.88 ± 2.18%, p < 0.05 vs. the other two groups). BclxL BH4 peptides, Apaf-1 inhibition or caspase inhibition failed to protect from apoptosis induced by the combination of inflammatory cytokines and bioincompatible PD fluids, although they protected from other forms of mesothelial cell apoptosis. Conclusion: Inflammation cooperates with high GDP PD fluids to promote mesothelial cell death, which is resistant to several therapeutic approaches. This information provides a framework for selection of PD fluid during peritonitis.

Keywords:
Apaf-1, Apoptosis, Biocompatibility, BclxL, Inflammation, Mesothelium, Peritoneal dialysis fluid
1.
Heimburger OBP (ed): Apparatus for peritoneal dialysis, ed 4; in Daugirdas JT, Blake PG, Ing TS (eds): Handbook of dialysis. Philadelphia, 2007, p 16.
2.
Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, Kuijper EJ, Li PK, Lye WC, Mujais S, Paterson DL, Fontan MP, Ramos A, Schaefer F, Uttley L: Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005;25:107-131.
3.
Di Paolo N, Sacchi G: Atlas of peritoneal histology. Perit Dial Int 2000;20(suppl 3):S5-S96.
4.
Verger C, Luger A, Moore HL, Nolph KD: Acute changes in peritoneal morphology and transport properties with infectious peritonitis and mechanical injury. Kidney Int 1983;23:823-831.
5.
Chen JY, Chi CW, Chen HL, Wan CP, Yang WC, Yang AH: TNF-alpha renders human peritoneal mesothelial cells sensitive to anti-Fas antibody-induced apoptosis. Nephrol Dial Transplant 2003;18:1741-1747.
6.
Catalan MP, Subira D, Reyero A, Selgas R, Ortiz-Gonzalez A, Egido J, Ortiz A: Regulation of apoptosis by lethal cytokines in human mesothelial cells. Kidney Int 2003;64:321-330.
7.
Santamaria B, Ucero AC, Reyero A, Selgas R, Ruiz-Ortega M, Catalan M, Egido J, Ortiz A: 3,4-Dideoxyglucosone-3-ene as a mediator of peritoneal demesothelization. Nephrol Dial Transplant 2008;23:3307-3315.
8.
Ortiz A, Catalan MP: Will modulation of cell death increase PD technique survival? Perit Dial Int 2004;24:105-114.
9.
Marchi E, Liu W, Broaddus VC: Mesothelial cell apoptosis is confirmed in vivo by morphological change in cytokeratin distribution. Am J Physiol Lung Cell Mol Physiol 2000;278:L528-L535.
10.
Heath RM, Jayne DG, O'Leary R, Morrison EE, Guillou PJ: Tumour-induced apoptosis in human mesothelial cells: a mechanism of peritoneal invasion by Fas Ligand/Fas interaction. Br J Cancer 2004;90:1437-1442.
11.
Janes KA, Albeck JG, Gaudet S, Sorger PK, Lauffenburger DA, Yaffe MB: A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science 2005;310:1646-1653.
12.
Santamaria B, Benito-Martin A, Ucero AC, Aroeira LS, Reyero A, Vicent MJ, Orzaez M, Celdran A, Esteban J, Selgas R, Ruiz-Ortega M, Cabrera ML, Egido J, Perez-Paya E, Ortiz A: A nanoconjugate Apaf-1 inhibitor protects mesothelial cells from cytokine-induced injury. PLoS One 2009;4:e6634.
13.
Ortiz A: Nephrology forum: apoptotic regulatory proteins in renal injury. Kidney Int 2000;58:467-485.
14.
Sanz AB, Santamaria B, Ruiz-Ortega M, Egido J, Ortiz A: Mechanisms of renal apoptosis in health and disease. J Am Soc Nephrol 2008;19:1634-1642.
15.
Strasser A, O'Connor L, Dixit VM: Apoptosis signaling. Annu Rev Biochem 2000;69:217-245.
16.
Ortiz A, Lorz C, Catalan MP, Danoff TM, Yamasaki Y, Egido J, Neilson EG: Expression of apoptosis regulatory proteins in tubular epithelium stressed in culture or following acute renal failure. Kidney Int 2000;57:969-981.
17.
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-489.
18.
Catalan MP, Esteban J, Subira D, Egido J, Ortiz A: Inhibition of caspases improves bacterial clearance in experimental peritonitis. Perit Dial Int 2003;23:123-126.
19.
Catalan MP, Reyero A, Egido J, Ortiz A: Acceleration of neutrophil apoptosis by glucose-containing peritoneal dialysis solutions: role of caspases. J Am Soc Nephrol 2001;12:2442-2449.
20.
Hotchkiss RS, McConnell KW, Bullok K, Davis CG, Chang KC, Schwulst SJ, Dunne JC, Dietz GP, Bahr M, McDunn JE, Karl IE, Wagner TH, Cobb JP, Coopersmith CM, Piwnica-Worms D: TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo. J Immunol 2006;176:5471-5477.
21.
Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, Yuan J: Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 2001;3:173-182.
22.
Lorz C, Justo P, Sanz AB, Egido J, Ortiz A: Role of Bcl-xL in paracetamol-induced tubular epithelial cell death. Kidney Int 2005;67:592-601.
23.
Lorz C, Ortiz A, Justo P, Gonzalez-Cuadrado S, Duque N, Gomez-Guerrero C, Egido J: Proapoptotic Fas ligand is expressed by normal kidney tubular epithelium and injured glomeruli. J Am Soc Nephrol 2000;11:1266-1277.
24.
Ortiz A, Ziyadeh FN, Neilson EG: Expression of apoptosis-regulatory genes in renal proximal tubular epithelial cells exposed to high ambient glucose and in diabetic kidneys. J Investig Med 1997;45:50-56.
25.
Santamaria B, Benito-Martin A, Ucero AC, Reyero A, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A: Bcl-xL prevents peritoneal dialysis solution-induced leukocyte apoptosis. Perit Dial Int 2008;28(suppl 5):S48-S52.
26.
Diaz C, Selgas R, Castro MA, Bajo MA, Fernandez de Castro M, Molina S, Jimenez C, Ortiz A, Vara F: Ex vivo proliferation of mesothelial cells directly obtained from peritoneal effluent: its relationship with peritoneal antecedents and functional parameters. Adv Perit Dial 1998;14:19-24.
27.
Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-Jimenez C, Jimenez-Heffernan JA, Aguilera A, Sanchez-Tomero JA, Bajo MA, Alvarez V, Castro MA, del Peso G, Cirujeda A, Gamallo C, Sanchez-Madrid F, Lopez-Cabrera M: Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003;348:403-413.
28.
Stylianou E, Jenner LA, Davies M, Coles GA, Williams JD: Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int 1990;37:1563-1570.
29.
Malet G, Martin AG, Orzaez M, Vicent MJ, Masip I, Sanclimens G, Ferrer-Montiel A, Mingarro I, Messeguer A, Fearnhead HO, Perez-Paya E: Small molecule inhibitors of Apaf-1-related caspase- 3/-9 activation that control mitochondrial-dependent apoptosis. Cell Death Differ 2006;13:1523-1532.
30.
Vicent MJ, Perez-Paya E: Poly-L-glutamic acid (PGA) aided inhibitors of apoptotic protease activating factor 1 (Apaf-1): an antiapoptotic polymeric nanomedicine. J Med Chem 2006;49:3763-3765.
31.
Sugioka R, Shimizu S, Funatsu T, Tamagawa H, Sawa Y, Kawakami T, Tsujimoto Y: BH4-domain peptide from Bcl-xL exerts anti-apoptotic activity in vivo. Oncogene 2003;22:8432-8440.
32.
Tauer A, Zhang X, Schaub TP, Zimmeck T, Niwa T, Passlick-Deetjen J, Pischetsrieder M: Formation of advanced glycation end products during CAPD. Am J Kidney Dis 2003;41(3 suppl 1):S57-S60.
33.
Dasgupta MK, Larabie M, Halloran PF: Interferon-gamma levels in peritoneal dialysis effluents: relation to peritonitis. Kidney Int 1994;46:475-481.
34.
Brauner A, Hylander B, Wretlind B: Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-1 receptor antagonist in dialysate and serum from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1996;27:402-408.
35.
McLoughlin RM, Witowski J, Robson RL, Wilkinson TS, Hurst SM, Williams AS, Williams JD, Rose-John S, Jones SA, Topley N: Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J Clin Invest 2003;112:598-607.
36.
Justo P, Sanz AB, Sanchez-Nino MD, Winkles JA, Lorz C, Egido J, Ortiz A: Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int 2006;70:1750-1758.
37.
Mondragon L, Galluzzi L, Mouhamad S, Orzaez M, Vicencio JM, Vitale I, Moure A, Messeguer A, Perez-Paya E, Kroemer G: A chemical inhibitor of Apaf-1 exerts mitochondrioprotective functions and interferes with the intra-S-phase DNA damage checkpoint. Apoptosis 2009;14:182-190.
38.
Linden T, Cohen A, Deppisch R, Kjellstrand P, Wieslander A: 3,4-Dideoxyglucosone-3-ene (3,4-DGE): a cytotoxic glucose degradation product in fluids for peritoneal dialysis. Kidney Int 2002;62:697-703.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.